News | Stents Drug Eluting | May 12, 2017

First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent

PinnacleHealth CardioVascular Institute offers new treatment for heart artery blockages

First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent

May 12, 2017 — PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and effectiveness of a new stent to treat patients with coronary heart disease who are at higher risk for bleeding.

Biosensors International Group Ltd is testing its BioFreedom drug-coated stent in the LEADERS FREE II Pivotal Study, with the therapeutic focus on patients at high bleeding risk (HBR) who can only receive an ultra-short dual anti-platelet regimen of only one month. William Bachinsky, M.D., FACC, medical director of cardiac catheterization labs at PinnacleHealth CardioVascular Institute, serves locally as principal investigator at PinnacleHealth.

Coronary artery disease is the narrowing or blockage of vessels that carry blood to the heart muscle, effecting millions of Americans and results in symptoms of shortness of breath, chest pain, heart attack and death. Blockages of the heart arteries are often treated with stents, thin metallic scaffolds that are implanted to help open the artery and alleviate these issues. Most patients require two anti-platelet medications for the first few months after the procedure, which for some patients is a concern because of an increased risk for bleeding. An option to reducing the length of time needed for these extra blood thinners would be favorable for HBR patients.

“We are very excited to be the first to treat a Pennsylvania patient in the global study testing a heart stent that may require shorter dual antiplatelet medication for patients with coronary heart disease,” said Bachinsky. “The polymer-free BioFreedom stent may allow us to address the unmet need of our patients, who are at higher risk for bleeding, but require treatment with an active stent.

The BioFreedom DES has CE mark approval and is commercialized outside of the United States. The LEADERS FREE II trial will be conducted at up to 85 clinical sites in the United States, Canada, Denmark, France, Germany, Italy and the United Kingdom.

Read the article “Biosensors Announces Enrollment of First Patient in New U.S. Pivotal BioFreedom Trial”

Read the article “Polymer-Free Drug-Coated Stents More Effective Than Bare-Metal Stents in High Bleeding Risk Patients”

Read the article “BioFreedom Trial Demonstrates Comparable Long-Term Safety, Efficacy to Conventional DES”

For more information: www.biosensors.com  

 

 

Related Content

Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
Overlay Init